Company Encyclopedia
View More
name
CEL-SCI
CVM.US
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
1.946 T
CVM.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cel-Sci Extends Shareholder Rights Agreement to 2030

    Cel-Sci Corporation has extended its Shareholder Rights Agreement until October 30, 2030, aiming to enhance shareholder interests and market stability. However, the company's stock (CVM) is rated as Underperform by TipRanks' AI Analyst due to ongoing financial struggles, including persistent losses and negative cash flows. Despite some positive technical momentum, the stock remains below key moving averages, making it less appealing for investors seeking stable returns. Current market cap stands at $56.43 million with an average trading volume of 190,652.

    Tip Ranks·
    US
    CVM
    +5.54%
    Tip Ranks·
    US
    CVM
    +5.54%

    CELSCI Corporation to Present at LD Micro Main Event Investor Conference

    CEL-SCI Corporation will present at the LD Micro Main Event Investor Conference in San Diego, CA, from October 19-21, 2025. CEO Geert Kersten is set to speak on October 21 at 9:30 a.m. PST, discussing the company's strategic roadmap for Multikine development. This announcement is for informational purposes only and should not be considered financial or legal advice.

    Reuters·
    US
    CVM
    +5.54%
    Reuters·
    US
    CVM
    +5.54%

    First Berlin Equity Research Reiterates BUY Rating for CEL-SCI Corporation, Sets Price Target at USD 60

    First Berlin Equity Research has reiterated a "BUY" rating for CEL-SCI Corporation, setting a price target of USD 60. Analyst Christian Orquera noted the company's pivotal moment in 2025, particularly with its lead immunotherapy, Multikine, aimed at head and neck cancer. The collaboration with Dallah Pharma is expected to boost Multikine's market potential in Saudi Arabia. Despite a price target reduction from USD 186 due to a reverse stock split, CEL-SCI is viewed as a de-risked player in immuno-oncology with several upcoming value catalysts.

    Reuters·
    US
    CVM
    +5.54%
    Reuters·
    US
    CVM
    +5.54%

    CEL-SCI Announces Closing of $10 Million Public Offering | CVM Stock News

    CEL-SCI Corporation has closed a public offering of 1,111,200 shares of common stock at $9.00 per share, raising approximately $10 million. The proceeds will be used for the development of Multikine, corporate purposes, and working capital. ThinkEquity acted as the sole placement agent. The offering was conducted under a shelf registration statement filed with the SEC. Multikine is designed to enhance the immune response in cancer patients before surgery and has received Orphan Drug designation from the FDA for specific cancer treatments.

    StockTitan·
    US
    CVM
    +5.54%
    StockTitan·
    US
    CVM
    +5.54%

    Drug developer CEL-SCI plunges after unveiling stock offering

    ** Cancer drug developer CEL-SCI's shares plunge 19.5% to $10.50 in extended trading** CVM unveils proposed public offering of stock and pre-funded warrants; size not disclosed** Proceeds from offering will be used to fund continued development of Multikine - its treatment for head and neck cancer - and other purposes** ThinkEquity acting as sole placement agent for the offering** CVM has 6.9 million outstanding shares for $89.7 million market cap, per LSEG data** As of last close, CVM stock up 8.7% YTD

    Reuters·
    US
    CVM
    +5.54%
    Reuters·
    US
    CVM
    +5.54%
    © 2025 Longbridge｜Disclaimer